Treprostinil for pulmonary arterial hypertension

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 5 Apr 2024: Trial registered, NCT06350032
  2. 31 Jul 2024: Trial started, NCT06350032

The trials

NCT06350032: Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

State
Under way
Phase
Phase 3
People
20 planned
Started
31 Jul 2024
Primary completion
Nov 2028
Arms
preservative-free parenteral treprostinil
Results
None posted
  1. 5 Apr 2024: Trial registered
  2. 31 Jul 2024: Trial started

NCT07177703: Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension

State
Not started
Phase
Phase 2
People
32 planned
Started
31 Oct 2025
Primary completion
31 Dec 2027
Arms
Treatment Group
Results
None posted
  1. 17 Sep 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Remodulin, Rumodolin, Tyvaso, Uniprost, preservative-free parenteral treprostinil, treprostinil SMI (treprostinil inhalation spray).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.